Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK Data
CRLAnaphylmNegative
AI Analysis
Summary
Aquestive Therapeutics received an FDA Complete Response Letter for Anaphylm with concerns regarding human factors and pharmacokinetic data, with the company targeting Q3 2026 for resubmission.
Outcome Details
FDA issued Complete Response Letter flagging human factors and pharmacokinetic data concerns
Importance:8/10
Sentiment:
-0.70
FDAregulatoryCRLresubmissionhuman factorspharmacokinetics
Related Companies
Read the original article
Published by yahoo_finance on March 11, 2026 6:04 AM